GLP-1RA is a modified incretin hormone that promotes satiety, potentiates insulin secretion, slows gut motility, and has anti-apoptotic and metabolic regulatory roles in many tissues.6,7 They are approved for treatment of type 2 diabetes (T2D) and obesity.7,8 GLP-1RA may directly or indirectly (by reduction of obesity and insulin resistance) protect against and/or treat NAFLD.9 In vitro studies suggest hepatocytes may express GLP-1 receptors and GLP-1RA directly reduce hepatic lipogenesis through AMPK signalling.10 The gene discussed is GIP; the disease is obesity due to melanocortin 4 receptor deficiency.